For the Inventor, By the Inventor

Enter assignee name

Zofingen, Switzerland

Siegfried Aktiengesellschaft

USPTO Granted Patents = 42

% Expired Patents = 2.4

EPO Patents = 18

Forward Citations = 192

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Kurt Thiele (22 out of 24 patents)

Ulrich Jahn (12 out of 13 patents)

Ludwig Zirngibl (11 out of 11 patents)

4. Rudolf Adrian (7 out of 7 patents)

5. Johanna Fischer (7 out of 7 patents)

6. Beat Theodor Weber (6 out of 24 patents)

7. Quazi Ahmed (6 out of 6 patents)

8. Rene Gnehm (5 out of 5 patents)

9. Jacques Meyer (3 out of 4 patents)

10. Georg Mixich (3 out of 3 patents)

11. Walter E Scharen (3 out of 3 patents)

12. Felix Geissmann (3 out of 4 patents)

13. Ben Pan (2 out of 3 patents)

14. Stefan Sahli (2 out of 4 patents)

15. Pascal Prinderre (2 out of 2 patents)

Core Competencies:

Buprenorphine

Nicotine

Opiates

Pharmaceutical Formulation

Synthesis

Enantiomeric Separation

Cholesterol-Lowering

Theophylline Derivatives

Herbicide

Fungicides

Anti-Mycotic

Bactericidal

42 patents: Sort by Forward Citations

1. 11407730 - Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps (2022-08-09),

2. 11279685 - Enantiomeric separation of racemic nicotine by addition of an O,O″-disubstituted tartaric acid enantiomer (2022-03-22),

3. 11104630 - Synthesis of mono-chlorinated acetophenone (2021-08-31),

4. 10927122 - Synthesis of noroxymorphone (2021-02-23),

5. 10391091 - Method of manufacturing buprenorphine and analogues thereof from oripavine (2019-08-27),

6. 10035807 - Method of manufacturing stereoisomers of buprenorphine and analogues thereof (2018-07-31),

7. 10034883 - Mesoporous dosage forms for poorly soluble drugs (2018-07-31),

8. 10010510 - Oral pharmaceutical formulation (2018-07-03),

9. 8921557 - Preparation of low impurity opiates in a continuous flow reactor (2014-12-30),

10. 4689233 - Coronary therapeutic agent in the form of soft gelatin capsules (1987-08-25),

11. 4668786 - P-fluorobenzoyl-piperidino alkyl theophylline derivatives (1987-05-26),

12. 4652659 - Method for the production of acemetacin (1987-03-24),

13. 4603204 - Theophylline derivatives (1986-07-29),

14. 4554356 - Method for production of imidazolyl vinyl ethers (1985-11-19),

15. 4550175 - Process for the stereospecific preparation of (1985-10-29),

Company Overview

Siegfried Aktiengesellschaft, headquartered in Zofingen, Switzerland, specializes in the development and manufacturing of active pharmaceutical ingredients and intermediates. The company focuses on advanced technologies such as racemic nicotine production, enantiomeric separation, and buprenorphine synthesis. Additionally, Siegfried is engaged in creating innovative dosage forms, including mesoporous structures, and is involved in the synthesis of cholesterol-lowering compounds and various chemical derivatives. Their expertise spans multiple therapeutic areas, emphasizing quality and efficiency in pharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

42 Patents

#1 in Zofingen

#329 in Switzerland

#16,354 in the World

Zofingen, Switzerland

Siegfried Aktiengesellschaft

Forward Citations = 192

41 inventors:

Kurt Thiele (22 out of 24 patents)

Ulrich Jahn (12 out of 13 patents)

Ludwig Zirngibl (11 out of 11 patents)

4. Rudolf Adrian (7 out of 7 patents)

5. Johanna Fischer (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Siegfried Aktiengesellschaft. Retrieved from https://idiyas.com/company/siegfried-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…